Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model

Therese Östberg, Kohki Kawane, Shigekazu Nagata, Huan Yang, Sangeeta Chavan, Lena Klevenvall, Marco E. Bianchi, Helena Erlandsson Harris, Ulf Andersson, Karin Palmblad

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective. High mobility group box chromosomal protein 1 (HMGB-1) is a DNA binding nuclear protein that can be released from dying cells and activated myeloid cells. Extracellularly, HMGB-1 promotes inflammation. Clinical and experimental studies demonstrate that HMGB-1 is a pathogenic factor in chronic arthritis. Mice with combined gene deficiency for DNase II and IFNRI spontaneously develop chronic, destructive polyarthritis with many features shared with rheumatoid arthritis. DNase II is needed for macrophage degradation of engulfed DNA. The aim of this study was to evaluate a potential pathogenic role of HMGB-1 in this novel murine model. Methods. The course of arthritis, assessed by clinical scoring and histology, was studied in DNase II -/- x IFNRI-/- mice, in comparison with heterozygous and wild-type mice. Synovial HMGB-1 expression was analyzed by immunohistochemistry. Serum levels of HMGB-1 were determined by Western immunoblotting and enzyme-linked immunosorbent assay (ELISA), and anti - HMGB-1 autoantibodies were detected by ELISA. Macrophage activation was studied by immunostaining for intracellular interleukin-1β and HMGB-1. HMGB-1 was targeted with truncated HMGB-1 - derived BoxA protein, acting as a competitive antagonist, with intraperitoneal injections every second day for 5 weeks. Results. DNase II -/- x IFNRI-/- mice developed symmetric polyarthritis with strong aberrant cytosolic and extracellular HMGB-1 expression in synovial tissue, in contrast to that observed in control animals. Increased serum levels of HMGB-1 and HMGB-1 auto-antibodies were recorded in DNase II-/- x IFNRI-/- mice, both prior to and during the establishment of disease. Systemic HMGB-1 - specific blockade significantly ameliorated the clinical disease course, and a protective effect on joint destruction was demonstrated by histologic evaluation. Conclusion. HMGB-1 is involved in the pathogenesis of this spontaneous polyarthritis, and intervention with an HMGB-1 antagonist can mediate beneficial effects.

Original languageEnglish
Pages (from-to)2963-2972
Number of pages10
JournalArthritis and Rheumatism
Volume62
Issue number10
DOIs
Publication statusPublished - Oct 2010

Fingerprint

High Mobility Group Proteins
HMGB1 Protein
Arthritis
Deoxyribonucleases
Enzyme-Linked Immunosorbent Assay
Macrophage Activation

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Östberg, T., Kawane, K., Nagata, S., Yang, H., Chavan, S., Klevenvall, L., ... Palmblad, K. (2010). Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis and Rheumatism, 62(10), 2963-2972. https://doi.org/10.1002/art.27590

Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. / Östberg, Therese; Kawane, Kohki; Nagata, Shigekazu; Yang, Huan; Chavan, Sangeeta; Klevenvall, Lena; Bianchi, Marco E.; Harris, Helena Erlandsson; Andersson, Ulf; Palmblad, Karin.

In: Arthritis and Rheumatism, Vol. 62, No. 10, 10.2010, p. 2963-2972.

Research output: Contribution to journalArticle

Östberg, T, Kawane, K, Nagata, S, Yang, H, Chavan, S, Klevenvall, L, Bianchi, ME, Harris, HE, Andersson, U & Palmblad, K 2010, 'Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model', Arthritis and Rheumatism, vol. 62, no. 10, pp. 2963-2972. https://doi.org/10.1002/art.27590
Östberg, Therese ; Kawane, Kohki ; Nagata, Shigekazu ; Yang, Huan ; Chavan, Sangeeta ; Klevenvall, Lena ; Bianchi, Marco E. ; Harris, Helena Erlandsson ; Andersson, Ulf ; Palmblad, Karin. / Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. In: Arthritis and Rheumatism. 2010 ; Vol. 62, No. 10. pp. 2963-2972.
@article{602fef98e0c64a1a8524568dba053997,
title = "Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model",
abstract = "Objective. High mobility group box chromosomal protein 1 (HMGB-1) is a DNA binding nuclear protein that can be released from dying cells and activated myeloid cells. Extracellularly, HMGB-1 promotes inflammation. Clinical and experimental studies demonstrate that HMGB-1 is a pathogenic factor in chronic arthritis. Mice with combined gene deficiency for DNase II and IFNRI spontaneously develop chronic, destructive polyarthritis with many features shared with rheumatoid arthritis. DNase II is needed for macrophage degradation of engulfed DNA. The aim of this study was to evaluate a potential pathogenic role of HMGB-1 in this novel murine model. Methods. The course of arthritis, assessed by clinical scoring and histology, was studied in DNase II -/- x IFNRI-/- mice, in comparison with heterozygous and wild-type mice. Synovial HMGB-1 expression was analyzed by immunohistochemistry. Serum levels of HMGB-1 were determined by Western immunoblotting and enzyme-linked immunosorbent assay (ELISA), and anti - HMGB-1 autoantibodies were detected by ELISA. Macrophage activation was studied by immunostaining for intracellular interleukin-1β and HMGB-1. HMGB-1 was targeted with truncated HMGB-1 - derived BoxA protein, acting as a competitive antagonist, with intraperitoneal injections every second day for 5 weeks. Results. DNase II -/- x IFNRI-/- mice developed symmetric polyarthritis with strong aberrant cytosolic and extracellular HMGB-1 expression in synovial tissue, in contrast to that observed in control animals. Increased serum levels of HMGB-1 and HMGB-1 auto-antibodies were recorded in DNase II-/- x IFNRI-/- mice, both prior to and during the establishment of disease. Systemic HMGB-1 - specific blockade significantly ameliorated the clinical disease course, and a protective effect on joint destruction was demonstrated by histologic evaluation. Conclusion. HMGB-1 is involved in the pathogenesis of this spontaneous polyarthritis, and intervention with an HMGB-1 antagonist can mediate beneficial effects.",
author = "Therese {\"O}stberg and Kohki Kawane and Shigekazu Nagata and Huan Yang and Sangeeta Chavan and Lena Klevenvall and Bianchi, {Marco E.} and Harris, {Helena Erlandsson} and Ulf Andersson and Karin Palmblad",
year = "2010",
month = "10",
doi = "10.1002/art.27590",
language = "English",
volume = "62",
pages = "2963--2972",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model

AU - Östberg, Therese

AU - Kawane, Kohki

AU - Nagata, Shigekazu

AU - Yang, Huan

AU - Chavan, Sangeeta

AU - Klevenvall, Lena

AU - Bianchi, Marco E.

AU - Harris, Helena Erlandsson

AU - Andersson, Ulf

AU - Palmblad, Karin

PY - 2010/10

Y1 - 2010/10

N2 - Objective. High mobility group box chromosomal protein 1 (HMGB-1) is a DNA binding nuclear protein that can be released from dying cells and activated myeloid cells. Extracellularly, HMGB-1 promotes inflammation. Clinical and experimental studies demonstrate that HMGB-1 is a pathogenic factor in chronic arthritis. Mice with combined gene deficiency for DNase II and IFNRI spontaneously develop chronic, destructive polyarthritis with many features shared with rheumatoid arthritis. DNase II is needed for macrophage degradation of engulfed DNA. The aim of this study was to evaluate a potential pathogenic role of HMGB-1 in this novel murine model. Methods. The course of arthritis, assessed by clinical scoring and histology, was studied in DNase II -/- x IFNRI-/- mice, in comparison with heterozygous and wild-type mice. Synovial HMGB-1 expression was analyzed by immunohistochemistry. Serum levels of HMGB-1 were determined by Western immunoblotting and enzyme-linked immunosorbent assay (ELISA), and anti - HMGB-1 autoantibodies were detected by ELISA. Macrophage activation was studied by immunostaining for intracellular interleukin-1β and HMGB-1. HMGB-1 was targeted with truncated HMGB-1 - derived BoxA protein, acting as a competitive antagonist, with intraperitoneal injections every second day for 5 weeks. Results. DNase II -/- x IFNRI-/- mice developed symmetric polyarthritis with strong aberrant cytosolic and extracellular HMGB-1 expression in synovial tissue, in contrast to that observed in control animals. Increased serum levels of HMGB-1 and HMGB-1 auto-antibodies were recorded in DNase II-/- x IFNRI-/- mice, both prior to and during the establishment of disease. Systemic HMGB-1 - specific blockade significantly ameliorated the clinical disease course, and a protective effect on joint destruction was demonstrated by histologic evaluation. Conclusion. HMGB-1 is involved in the pathogenesis of this spontaneous polyarthritis, and intervention with an HMGB-1 antagonist can mediate beneficial effects.

AB - Objective. High mobility group box chromosomal protein 1 (HMGB-1) is a DNA binding nuclear protein that can be released from dying cells and activated myeloid cells. Extracellularly, HMGB-1 promotes inflammation. Clinical and experimental studies demonstrate that HMGB-1 is a pathogenic factor in chronic arthritis. Mice with combined gene deficiency for DNase II and IFNRI spontaneously develop chronic, destructive polyarthritis with many features shared with rheumatoid arthritis. DNase II is needed for macrophage degradation of engulfed DNA. The aim of this study was to evaluate a potential pathogenic role of HMGB-1 in this novel murine model. Methods. The course of arthritis, assessed by clinical scoring and histology, was studied in DNase II -/- x IFNRI-/- mice, in comparison with heterozygous and wild-type mice. Synovial HMGB-1 expression was analyzed by immunohistochemistry. Serum levels of HMGB-1 were determined by Western immunoblotting and enzyme-linked immunosorbent assay (ELISA), and anti - HMGB-1 autoantibodies were detected by ELISA. Macrophage activation was studied by immunostaining for intracellular interleukin-1β and HMGB-1. HMGB-1 was targeted with truncated HMGB-1 - derived BoxA protein, acting as a competitive antagonist, with intraperitoneal injections every second day for 5 weeks. Results. DNase II -/- x IFNRI-/- mice developed symmetric polyarthritis with strong aberrant cytosolic and extracellular HMGB-1 expression in synovial tissue, in contrast to that observed in control animals. Increased serum levels of HMGB-1 and HMGB-1 auto-antibodies were recorded in DNase II-/- x IFNRI-/- mice, both prior to and during the establishment of disease. Systemic HMGB-1 - specific blockade significantly ameliorated the clinical disease course, and a protective effect on joint destruction was demonstrated by histologic evaluation. Conclusion. HMGB-1 is involved in the pathogenesis of this spontaneous polyarthritis, and intervention with an HMGB-1 antagonist can mediate beneficial effects.

UR - http://www.scopus.com/inward/record.url?scp=77957672480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957672480&partnerID=8YFLogxK

U2 - 10.1002/art.27590

DO - 10.1002/art.27590

M3 - Article

VL - 62

SP - 2963

EP - 2972

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 10

ER -